Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.

Gray, Glenda; Collie, Shirley; Goga, Ameena; Garrett, Nigel; Champion, Jared; Seocharan, Ishen; Bamford, Lesley; Moultrie, Harry; Bekker, Linda-Gail

Gray, Glenda; Collie, Shirley; Goga, Ameena; Garrett, Nigel; Champion, Jared; Seocharan, Ishen; Bamford, Lesley; Moultrie, Harry; Bekker, Linda-Gail.

Gray G; South African Medical Research Council, Cape Town, South Africa.
Collie S; Discovery Health, Sandton, South Africa.
Goga A; South African Medical Research Council, Cape Town, South Africa.
Garrett N; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Champion J; Discovery Health, Sandton, South Africa.
Seocharan I; South African Medical Research Council, Cape Town, South Africa.
Bamford L; National Department of Health, Pretoria, South Africa.
Moultrie H; National Institute for Communicable Diseases, Johannesburg, South Africa.
Bekker LG; University of Cape Town, Cape Town, South Africa linda-gail.bekker@hiv-research.org.za.

N Engl J Med ; 386(23): 2243-2245, 2022 06 09.

Article in English | MEDLINE | ID: covidwho-1830281

Subject(s)

Ad26COVS1; BNT162 Vaccine; COVID-19; Ad26COVS1/therapeutic use; BNT162 Vaccine/therapeutic use; COVID-19/prevention & control; Humans; SARS-CoV-2; South Africa; Vaccine Efficacy; Vaccines/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine / Ad26COVS1 Type of study: Experimental Studies Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Africa Language: English Journal: N Engl J Med Year: 2022 Document Type: Article Affiliation country: NEJMc2202061

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google